Adding Chinese herbal medicine to antibiotic treatment for acute exacerbation of chronic obstructive pulmonary disease

抗生素加用中草药治疗慢性阻塞性肺疾病急性加重

• 批准号: 104983
• 金额: $ 94.56万
• 依托单位: PHOENIX MEDICAL LTD.
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104983
• 关键词: Adding; Chinese; herbal; medicine; antibiotic

Over 25 million people in China had Chronic Obstructive Pulmonary Disease (COPD) in 2010, and this isprojected to increase to over 42 million by 2020. Every year, the average COPD patient experiences 2-3 severeepisodes called "acute exacerbations" (AECOPD). These are often caused by bacteria and treated withantibiotics, but many of these bacteria (especially in China) no longer respond to the commonest antibiotics,leading to prolonged hospital admissions and more deaths. Shufung Jiedu (SJ), a Traditional Chinese Medicineconsisting of 8 traditional Chinese herbs, is already on the market in China. Preliminary research suggests that itcan reduce risk of hospitalisation and duration of hospitalisation in patients with AECOPD, and so it couldreduce the risk of antibiotic resistance. In this project we will conduct research in parallel in the UK and Chinato test the effect of SJ in tackling antibiotic resistance in AECOPD, both in laboratory models and in clinicaltrials. If successful, the results will support the inclusion of SJ in guidelines for the treatment for AECOPD bothin China and in the UK, which will open up a very large market for the product.

2010年，中国有超过2500万人患有慢性阻塞性肺疾病（COPD），预计到2020年将增加到4200万人以上。每年，平均COPD患者经历2-3次称为“急性加重”（AECOPD）的严重发作。这些通常是由细菌引起的，并用抗生素治疗，但其中许多细菌（特别是在中国）不再对最常见的抗生素产生反应，导致住院时间延长和死亡人数增加。疏风解毒是一种由8种中草药组成的中药，已在中国上市。初步研究表明，它可以降低AECOPD患者的住院风险和住院时间，因此可以降低抗生素耐药性的风险。在这个项目中，我们将在英国和中国进行平行研究，以测试SJ在实验室模型和临床试验中应对AECOPD抗生素耐药性的效果。如果成功，结果将支持SJ纳入中国和英国AECOPD治疗指南，这将为该产品打开一个非常大的市场。